Answers are grounded in this paper and cite their sources.
The lung is the largest organ exposed to the environment. It has an alveolar surface area of around 70 m2 and comprises a complex series of branches leading to gas exchanging units that are critical to life.1 It is a very adaptable organ and exchanges 10 000 L of air/day. In addition, it can increase oxygen consumption from 250 to 5500 mL/min and blood flow from 4 to 40 L/min.1 This significant capacity to adapt has conferred an evolutionary survival advantage as we can respond to ventilatory stresses in our ‘fight or flight’ response. The lung has many other roles with host defence being of major importance, and these need to be considered when disease management arises. The lung begins at the nasal passages and through a series of branches ends with the alveoli. The extensive branching of the trachea to bronchioles serves to filter potentially harmful organic and inorganic environmental agents. Branching also increases the area for gas exchange. However, the diffuse structure of the lung makes it susceptible to a variety of diseases that affect all locations. This unique organ can present with anatomically specific conditions such as allergic rhinitis and sinusitis that are distinct from bronchitis, bronchiolitis or diseases affecting the alveoli such as hypersensitivity pneumonitis. In addition, the pleura and mediastinum are further sites for disease. Apart from the anatomical location of disease, the common drivers of pathology fall into the usual broad categories of: infective, inflammatory, malignant, occupational, toxic/environmental and developmental, while the time course can be classified as acute, subacute, and chronic-stable or progressive. The major lung diseases include cystic fibrosis, chronic obstructive pulmonary disease, bronchiectasis, asthma, pneumonia, lung cancer, tuberculosis, acute lung injury, idiopathic pulmonary fibrosis, sarcoidosis, interstitial pneumonias and occupational lung disease. There are no cures for these diseases or we do not fully understand their aetiology and pathogenesis. Chronic respiratory diseases cause approximately 7% of all deaths worldwide and represent 4% of the global burden of disease with major associations between diseases such as tuberculosis and human immunodeficiency virus/acquired immune deficiency syndrome, influenza and asthma, chronic obstructive pulmonary disease and lung cancer, and lung infection and acute lung injury.2, 3 Although it will be the third leading cause of death worldwide by 2020, chronic obstructive pulmonary disease is frequently not diagnosed or its severity underestimated.4 In the US, chronic lung diseases represent $154 billion in health-care costs each year. The cost of lung disease runs into hundreds of billions of dollars globally each year and threatens to overwhelm public health services.5 This is compounded by nearly half of the world's population being exposed to poor air quality. Notably, tobacco is still legal despite tobacco smoking being responsible for the death of more than 5 million people each year, including 1.3 million from lung cancer, and adversely influencing the health of hundreds of thousands who are exposed to its second-hand effects.4 The range of conditions affecting the lung ensures that lung illnesses remains among the top five causes of disease in all communities worldwide. Inflammation is a critical first step in many diseases. It is caused by both infective and non-infective causes. An injury, such as incurred from cigarette smoke or infection, usually causes infiltration by neutrophils, lymphocytes and macrophages at the site. There is injury of structural cells including the epithelium, endothelium and mesenchyme of the lung. Central to a normal repair are two major processes: epithelium and endothelium restitution, and an intact basement membrane on which the epithelial and endothelial cells can proliferate and repair damaged tissue. If the epithelial and endothelial repair is normal, the lung is able to return to normal function. However if there is inadequate restitution of these tissues, then a fibroproliferative phase occurs in which the lung develops scar tissue that limits the extension of injury.6, 7 Although collagen I is the predominant extracellular matrix deposited, there are other extracellular matrices also present. Early collagen deposition may be reversible, while chronic collagen deposition is irreversible and, in the lung, leads to airway remodelling and loss of gas exchange units. Furthermore, with smoking, there is increased matrix metalloproteinase production and decreased tissue inhibitors of matrix metalloproteinase production that results in elastin breakdown.8 Elastin is a critical extracellular matrix for lung mechanics, and the loss of elastin causes gas trapping and chest hyperinflation. Smoking also causes airway inflammation and epithelial as well as endothelial damage. Repair leads to recovery of the lung; however, progressive lung disease is a major cause of morbidity and mortality. The mechanisms of disease progression need to be elucidated. One of several potential factors causing ongoing injury is increased oxidative stress. Recently, it was shown that cellular senescence upregulated the expression of adhesion molecules, thereby promoting inflammation. Other mechanisms include impaired telomerase function resulting in defective repair due to cellular senescence.9 The interaction of bacteria with the diseased lung is becoming increasingly important. In cystic fibrosis, for example, there is dehydration of the air surface liquid layer, the accumulation of tenacious secretions and the formation of biofilms by bacteria. The defective clearance of bacteria would also influence the inflammatory response, impair repair and would result in progressive lung damage.10 Therefore, epithelial and endothelial restitution or the replacement of defective tissue is critical for normal repair. For airway diseases, therapies are limited to bronchodilators and inhaled steroids.11 The bronchodilators include beta adrenergic agents and anticholinergics. Recently, long-acting and ultralong-acting inhalers have been developed.12 Inhaled corticosteroids have been used with success in asthma but have limited effects in chronic obstructive pulmonary disease, cystic fibrosis and bronchiectasis.13 Oral steroids, despite their side-effects, are still used in inflammatory and interstitial lung diseases. Anti-inflammatory agents such as azathioprine and cyclophosphamide are also used for interstitial lung disease. The role of newer anti-inflammatory agents such as mycophenolate and sirolimus are evolving.14 Previously, they were used mainly in post-transplant management but are now increasingly used in managing other lung diseases. Biological agents such as humanized monoclonal antibodies, including anti-immunoglobulin E and anti-interleukin 5 for asthma and anti-tumour necrosis factor α for sarcoidosis15, 16 are also increasingly effective. There is a limited number of antifibrotic agents. Interferon γ, which was initially promising, has not been shown to be useful for lung fibrosis in clinical trials. Pirfenidone, an anti-transforming growth factor β agent has shown some efficacy in the management of idiopathic pulmonary fibrosis.16 Notably, there is no effective treatment for acute lung injury. Certain therapies are useful for certain diseases. Inhaled bronchodilators and corticosteroids are effective in most phenotypes of asthma, while immunomodulating therapies are useful for several lung diseases driven by inflammation. However, these agents do not address effective wound repair by augmenting epithelial and endothelial restitution. They address aspects of the complex inflammatory pathways but not structural consequences of injury. Therefore, they do not directly impact on the formation of healthy airway or gas exchanging units. In addition, the agents have significant side-effects that limit their use. Furthermore, we use these agents across the spectrum of lung diseases, while there is a need for ‘personalized’ medicine. In chronic and progressive lung diseases, the treatments are ineffective, and lung transplantation is the only viable option. A stem cell is a cell that is usually derived from a clonal population has unlimited doubling and can differentiate into many cell types.17 These cells can also influence the inflammatory pathways and/or replace damaged lung tissue. Several cells have been shown to be significantly anti-inflammatory. These include mesenchymal stem cells (MSC) derived from different sources18 and cells derived from the placenta.19 Embryonic stem cells (ESC) and induced pluripotent cells (iPS) have the potential for differentiation into lung cells. ESC is derived from the blastocyst and can differentiate into cells from all three germ layers. Therefore, there has been a strong focus on differentiating these cells into lung cells. The Nobel Prize for Physiology and Medicine 2012 was awarded to two scientists for their pioneering work on cellular reprogramming. Professor Yamanaka created iPS by transfecting fibroblasts with four genes critical to the pluripotent state: c-myc, Klf4, Oct4 and Sox-2.20 The iPS cells have similar properties to ESC and are pluripotent. As these cells are derived from an individual's own fibroblasts, they bypass the significant issue of rejection during cell transplantation.21 In addition, both ESC and iPS can be derived to investigate genetic diseases for therapeutic purposes. A cystic fibrosis line could be generated to investigate the interactions and interrelationships between the genotype and phenotype as well as to test therapeutic agents in an individualized cell line of this disease. Recently innovative experiments have been undertaken to repopulate a decellularized matrix of the lung. In this model, a matrix was derived from a rat lung, and epithelium and endothelium were cultured and propagated on this matrix.22 Whole lung was formed and transplanted into a rodent with the animal surviving. With iPS, this provides an opportunity to decellularize a lung and fabricate a whole lung from the patients' own cells. Different stem cells have different therapeutic properties. The anti-inflammatory properties of MSC are a tremendous advantage in inflammatory diseases. In addition, MSC may have trophic effects that improve the repair of epithelial and endothelial cells. Significantly, placenta-derived cells also have anti-inflammatory properties and some capacity to differentiate.19 Placenta-derived cells are abundantly available. ECS and iPS can differentiate into lung tissue and form the basis for lung regeneration. This could be pursued either with the view to specific cell replacement or alternatively with the aim of organ fabrication using decellularized matrix. It is important to appreciate that stem cells can have multiple benefits at several levels. They can reduce inflammation, augment repair and create new lung tissue. As such, stem cells could significantly extend present therapeutic options by addressing fundamental issues relating to disease progression and loss of healthy airways or gas-exchange units. As with all therapies, the potential for adverse effects always exist. However, progress has been made in cellular therapy that confirms that MSC is safe for human application. Tumour formation is a concern for ESC and iPS.23 ESC can form teratomas, and a single cell is sufficient to cause this outcome following cell transplantation. iPS may have some genetic instability and might have the potential for tumourogenesis.23 Although studies using MSC have not revealed any significant rejection, this still remains a possibility for all adult stem cells and ESC that are differentiated for transplantation. The most controversial cell line is ESC because they are derived from a blastocyst and an embryo is destroyed in the process. The ethical implications regarding the loss of the embryo are complex. However, iPS may solve the ethical problems associated with ESC. Adult stem cells derived from adult tissue are relatively free of ethical issues. The fabrication of organs using cadaveric lung may hold ethical implications because people may be induced to donate lungs following death for pecuniary gain. Furthermore, medical tourism does have ethical implications. Many patients with a chronic and progressive condition are desperate for assistance and would fall prey to clinics selling ‘miracle cures’ using stem cell therapy. It is unethical to sell unrealistic expectations to patients, and this practice would require further regulation. In this series, we have invited world experts to provide their insights into cell therapy of the lung. We will examine the role of the developmental pathways in differentiating ESC and iPS into lung tissue. The role of stem cells in the treatment of acute as well as chronic lung disease will be explored. The potential for lung fabrication from stem cells will be reviewed. Lung cancer is a major cause of mortality, and the existence of cancer stem cells will be discussed as well as the capacity to target these cells, which would have important therapeutic potential. We will also investigate the controversies of ESC and iPS as well as ethical aspects with regard to stem cell therapy. The first of these reviews24 appears in this issue of Respirology and discusses the role of MSC in the cellular therapy of lung disease. MSC is derived from a variety of sources and have significant anti-inflammatory properties that could play a major role in the treatment of lung disease.
No takes yet. Share an insight, caveat, or question.
Moodley et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: